SMC2 Antibody

What is SMC2 and what is its biological significance?

SMC2 is a core subunit of the condensin complex that plays an essential role in DNA supercoiling and chromosome condensation during cell division. It forms a heterodimer with SMC4, which serves as the foundation of the condensin complex . This protein is critical for embryonic stem cell survival and proper chromosomal segregation during mitosis . SMC2 has been extensively studied because of its involvement in multiple cellular processes including:

• DNA supercoiling and chromosome compaction

• Sister chromatid segregation during cell division

• Regulation of gene expression during interphase

• Maintenance of chromosomal stability

Research demonstrates that SMC2 is predominantly located in the cytoplasm during cell interphase, with only a minor amount remaining associated with chromatin in the nucleus .

What antibodies are commonly used for SMC2 detection in research?

Several validated antibodies are utilized for SMC2 detection across different experimental applications:

The specificity of antibodies like ab10412 has been confirmed through immunocytochemistry comparing wild-type versus SMC2-depleted cells . When selecting an antibody, researchers should consider validation data and appropriate controls for their specific experimental system.

What are the optimal protocols for SMC2 detection by Western blotting?

For effective Western blot detection of SMC2:

• Sample preparation: Standard protein extraction methods are suitable, with actin commonly used as a loading control.

• Antibody selection and dilution:

  • Primary antibodies: anti-SMC2 (ab10412, Abcam or 07-710, Upstate-Millipore) at 1:1000 dilution

  • Secondary antibodies: HRP-conjugated anti-mouse (P0447, Dako) or anti-rabbit (P0217, Dako) as appropriate for the primary antibody

• Detection method: Enhanced chemiluminescence followed by quantification using image analysis software such as the GeneTools Program (SynGene)

• Important considerations:

  • Include positive and negative controls

  • When investigating condensin complex components, consider blotting for partner proteins (SMC4, NCAPH) to establish correlation of expression levels

  • SMC2 and SMC4 protein levels show strong positive correlation in clinical samples and cancer cell lines

How should immunohistochemistry for SMC2 be performed on tissue samples?

Optimized immunohistochemistry protocol for SMC2 detection:

• Tissue preparation: Use paraffin-embedded tissue sections (4-5 μm thickness)

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer, pH 6.0

• Detection system: EnVision + Dual Link System-HRP, DAB+ (Dako) or equivalent

• Primary antibody: Anti-SMC2 antibody (ab10412, Abcam) at 1:200 dilution

• Counterstaining: Hematoxylin for nuclear visualization

• Controls: Include both positive controls (tissues known to express SMC2) and negative controls (SMC2-depleted cells or antibody omission)

For dual labeling studies, consider combining SMC2 staining with β-catenin (610154, BD Transduction Laboratories) to assess co-expression patterns, particularly in cancer tissues where the WNT pathway is activated .

How is SMC2 expression regulated at the transcriptional level?

SMC2 transcription is regulated through multiple mechanisms:

• WNT/β-catenin pathway regulation:

  • The SMC2 promoter is a direct target of the β-catenin·TCF4 transcription complex

  • Activation of the WNT pathway leads to increased SMC2 expression

  • This mechanism explains why SMC2 is frequently overexpressed in WNT-activated hyperplastic cells

• MYCN regulation:

  • In neuroblastoma, SMC2 is transcriptionally regulated by the MYCN oncogene

  • MYCN amplification correlates with increased SMC2 expression

  • SMC2 cooperates with MYCN to regulate DNA damage response genes

• Quantification methods:

  • qPCR primers for SMC2 expression analysis:

    • Forward: 5′ AAT GAG CTG CGG GCT CTA GA 3′

    • Reverse: 5′ TTG TTG CTT GTG ATA TGA GCT TTG 3′

  • Standard housekeeping genes for normalization: GAPDH and Actin

Understanding these regulatory mechanisms provides insight into the context-dependent expression of SMC2 in normal and pathological conditions.

What is the relationship between SMC2 expression and cancer development?

SMC2 shows altered expression in multiple cancer types with significant implications:

• Colorectal cancer (CRC):

  • Up-regulated in 69% of tumor samples compared to matched normal controls (protein level)

  • 68.5% of cases show increased SMC2 mRNA expression

  • Correlates with SMC4 overexpression in 48.1% of CRC cases

• Other cancer types:

  • Overexpressed in gastric cancer, lymphoma, and some types of neuroblastoma

  • Suggested as a risk biomarker in pancreatic cancers

  • Correlated with MYCN amplification in neuroblastoma

• Functional significance:

  • SMC2/SMC4 protein levels negatively correlate with population doubling times in CRC cell lines

  • Knockdown of SMC2 drastically reduces tumor growth in colorectal cancer mouse models

  • In neuroblastoma, SMC2 downregulation induces DNA damage and shows synergistic lethal effects in MYCN-amplified/overexpression cells, leading to apoptosis

• Prognostic value:

  • In neuroblastoma, patients with MYCN-amplified tumors show improved survival when SMC2 expression is low

These findings establish SMC2 as both a biomarker and potential therapeutic target across multiple cancer types.

What are effective methods for SMC2 knockdown in experimental systems?

Multiple validated approaches for SMC2 silencing include:

• Transient siRNA knockdown:

  • Recommended siRNA: Qiagen catalog no. SI02654260

  • Transfection reagent: HiPerfect Transfection Reagent (Qiagen) using 20 μM siRNA

  • For extended experiments, consider a second round of transfection after 48-72 hours

  • Include scrambled siRNA controls (Qiagen catalog no. 1027281)

• Stable shRNA knockdown:

  • Lentiviral transduction with shRNAs targeting SMC2 (MISSION shRNA, Sigma-Aldrich)

  • Validated clone IDs: NM_006444.1-3720s1c1, -1295s1c1, -1961s1c1, -3173s1c1, and -3300s1c1

  • Select transduced cells with puromycin

  • Confirm knockdown efficiency by qPCR and Western blot

• Verification of knockdown efficiency:

  • Western blot with anti-SMC2 antibodies

  • qPCR using SMC2-specific primers

  • Immunocytochemistry to visualize protein reduction

For optimal results, knockdown efficiency should be determined 48-72 hours post-transfection, and phenotypic assays should be performed within the validated window of knockdown effect.

How do SMC2 depletion experiments impact cell division and chromosome structure?

SMC2 depletion produces several measurable phenotypes:

• Effects on cell cycle:

  • G1 cell cycle arrest observed in HCT116 colorectal cancer cells upon SMC2 inhibition

  • Impaired chromosome condensation during mitosis

  • Defects in cytokinesis resulting in binucleate or polyploid cells

• Quantifiable changes:

  • Increased frequency of polyploid cells (from 3% to 20% within 30 hours of SMC2 depletion)

  • Abnormal chromosome morphology during metaphase

  • Reduced cellular proliferation rates in WNT-activated cells

• Differential effects of condensin I vs. condensin II depletion:

  • SMC2 depletion affects both condensin complexes

  • CAP-H (condensin I) depletion shows delayed polyploidy compared to CAP-D3 (condensin II) depletion

  • Cross-dependency studies indicate that depletion of one condensin complex does not block localization of the other

These findings highlight the essential role of SMC2 in maintaining chromosomal integrity and proper cell division.

What approaches can target SMC2 for potential cancer therapeutics?

Several innovative strategies for targeting SMC2 in cancer therapy include:

• Antibody-based approaches:

  • Intracellular delivery of anti-SMC2 antibodies using polymeric micelles (PM) based on Pluronic F127 amphiphilic polymers

  • This approach increases antibody stability and facilitates cellular internalization

  • Demonstrated efficacy in cytotoxicity and inhibition of tumorsphere formation in MDA-MB-231 (breast) and HCT116 (colon) cancer cell lines

• Combination therapy strategies:

  • Anti-SMC2 micelles combined with standard chemotherapeutics:

    • Paclitaxel (PTX) for breast cancer models

    • 5-Fluorouracil (5-FU) for colorectal cancer models

  • The efficacy of both encapsulated drugs is higher than their free forms

  • Micelles loaded with Ab-SMC2 and PTX showed the highest efficacy in inhibiting tumorsphere formation in HCT116 cells

• Pharmacodynamic considerations:

  • SMC2 inhibition is particularly effective against cancer stem cells (CSCs)

  • Enhanced targeting of the tumoral subpopulation responsible for tumor recurrence and metastasis

  • Synergistic effects observed in MYCN-amplified neuroblastoma cells

These therapeutic approaches represent promising directions for exploiting SMC2 as a molecular target in cancer treatment.

How can researchers evaluate SMC2's role in cancer stem cell biology?

Specialized methodologies for investigating SMC2 in cancer stem cells include:

• Tumorsphere formation assay:

  • Seed 1000 cells in ultra-low attachment 96-well plates following SMC2 inhibition

  • Cultivate in sphere growth media (serum-free with defined growth factors)

  • Quantify sphere formation after 5-7 days

  • This assay specifically measures the self-renewal capacity of cancer stem cells

• SMC2 knockdown in sphere formation studies:

  • Implement a 2-step siRNA approach to ensure sustained SMC2 inhibition

  • First treatment with SMC2-siRNA using Lipofectamine 2000

  • Second identical treatment after 72 hours

  • Harvest cells 6 hours after second transfection for sphere formation assay

• Combined analysis approaches:

  • Flow cytometry for stem cell markers in SMC2-inhibited populations

  • Analysis of gene expression patterns in tumorspheres vs. adherent cells

  • Assessment of drug resistance phenotypes in relation to SMC2 expression

These methodologies provide robust tools for evaluating the functional significance of SMC2 in maintaining cancer stem cell properties.

What is the relationship between SMC2 and DNA damage response pathways?

SMC2 has important connections to DNA damage response (DDR) mechanisms:

• Transcriptional regulation of DDR genes:

  • SMC2 cooperates with MYCN to regulate DNA damage response genes in neuroblastoma

  • This cooperation may explain the increased vulnerability of MYCN-amplified cells to SMC2 inhibition

• DNA damage induction:

  • Downregulation of SMC2 induces DNA damage in MYCN-amplified/overexpression neuroblastoma cells

  • This leads to a synergistic lethal response and apoptosis

• Experimental assessment:

  • DNA damage can be evaluated by:

    • γH2AX immunostaining to detect double-strand breaks

    • Comet assay to measure DNA fragmentation

    • Analysis of checkpoint activation (pCHK1, pCHK2)

  • Cell death can be quantified through:

    • Annexin V/PI staining followed by flow cytometry

    • Caspase activation assays

    • PARP cleavage detection by Western blot

This connection between SMC2 and DNA damage response offers a mechanistic explanation for the therapeutic potential of targeting SMC2, particularly in cancers with specific genetic alterations like MYCN amplification.

How should researchers evaluate antibody specificity for SMC2 detection?

Rigorous validation of SMC2 antibodies is essential for reliable research:

• Recommended validation approaches:

  • Western blot comparison of wild-type versus SMC2-depleted cells

  • Immunocytochemistry of wild-type versus SMC2-depleted cells (as demonstrated with ab10412 antibody)

  • Pre-absorption with recombinant SMC2 protein

  • Peptide competition assays

• Controls to include:

  • Positive controls: tissues/cells known to express SMC2

  • Negative controls: SMC2-knockdown cells

  • Technical controls: antibody omission control

• Cross-reactivity assessment:

  • Test against related SMC family proteins, particularly SMC4

  • Confirm specificity using multiple antibodies targeting different epitopes

  • Consider species cross-reactivity if working with multiple model organisms

Proper antibody validation ensures experimental reliability and reproducibility in SMC2 research.

What are the most informative experimental models for studying SMC2 function?

Different experimental systems offer distinct advantages for SMC2 research:

• Cancer cell line models:

  • Colorectal cancer: DLD-1, HCT116 (validated for SMC2 studies)

  • Breast cancer: MDA-MB-231 (validated for SMC2 studies)

  • Neuroblastoma: MYCN-amplified cell lines (particularly informative for SMC2 and MYCN interactions)

• Patient-derived samples:

  • Primary tumor tissues compared to matched normal samples

  • Analysis demonstrates 69% of colorectal tumors show SMC2 overexpression

  • Patient-derived xenografts for in vivo functional studies

• 3D culture systems:

  • Tumorsphere assays particularly useful for studying cancer stem cell properties in relation to SMC2

  • Organoid models for more physiologically relevant assessments

• In vivo models:

  • SMC2 knockdown in mouse xenograft models shows reduced tumor growth in colorectal cancer

  • Conditional knockout models for studying tissue-specific effects

Selection of appropriate models should be guided by the specific research question, with consideration of the cancer type and molecular context (such as WNT activation or MYCN amplification) most relevant to SMC2 function.